11 research outputs found

    The causes, consequences, and treatment of left or right heart failure

    Get PDF
    Chronic heart failure (HF) is a cardiovascular disease of cardinal importance because of several factors: a) an increasing occurrence due to the aging of the population, primary and secondary prevention of cardiovascular events, and modern advances in therapy, b) a bad prognosis: around 65% of patients are dead within 5 years of diagnosis, c) a high economic cost: HF accounts for 1% to 2% of total health care expenditure. This review focuses on the main causes, consequences in terms of morbidity, mortality and costs and treatment of HF

    Augustus ou le dilemme du risque hémorragique et ischémique chez les patients atteints d'une fibrillation auriculaire

    No full text
    The choice of antithrombotic treatment for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention is a challenge today. Oral anticoagulation is indicated for the prevention of stroke and systemic embolism in patients with atrial fibrillation, but it has not been shown to prevent stent thrombosis and is generally not indicated for secondary prevention after acute coronary syndrome. The objective of the AUGUSTUS study was to evaluate the efficacy of Apixaban versus a vitamin K antagonist and aspirin versus placebo against a concomitant treatment with a P2Y12 inhibitor in this specific population. In this context, this randomized study has provided further evidence in favour of Apixaban treatment and Aspirin suppression with respect to the number of ischemic events and rates of major bleeding.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

    Lead extraction in non-cardiac surgery centers: Easier said than done

    No full text
    SCOPUS: ed.jinfo:eu-repo/semantics/publishe

    Jet Ventilation Reduces Coronary Sinus Movement in Patients Undergoing Atrial Fibrillation Ablation: An Observational Crossover Study.

    No full text
    One of the reasons that high-frequency jet ventilation (HFJV) is used is due to the near immobility of thoracic structures. However, no study has quantified the movements of cardiac structures during HFJV compared with normal mechanical ventilation.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

    Jet Ventilation Reduces Coronary Sinus Movement in Patients Undergoing Atrial Fibrillation Ablation: An Observational Crossover Study

    No full text
    Background: One of the reasons that high-frequency jet ventilation (HFJV) is used is due to the near immobility of thoracic structures. However, no study has quantified the movements of cardiac structures during HFJV compared with normal mechanical ventilation. Methods: After ethical approval and written informed consent, we included 21 patients scheduled for atrial fibrillation ablation in this prospective crossover study. Each patient was ventilated with both normal mechanical ventilation and HFJV. During each ventilation mode, displacements of the cardiac structure were measured by the EnSite Precision mapping system using a catheter placed in the coronary sinus. Results: The median [Q1–Q4] displacement was 2.0 [0.6–2.8] mm during HFJV and 10.5 [9.3–13.0] mm during conventional ventilation (p < 0.000001). Conclusion: This study quantifies the minimal movement of cardiac structures during HFJV compared to standard mechanical ventilation

    Electroanatomical mapping improves procedural outcomes of cryoballoon pulmonary vein isolation (the Achieve Plus study).

    No full text
    BACKGROUND: Validation of pulmonary vein (PV) isolation (PVI) using only the Achieve catheter following cryoballoon ablation (CBA) is imperfect since pulmonary vein potentials (PVP) can be recorded in only 50-85% of the veins and residual PVP are found in up to 4.3-7.6% of the isolated veins in remapping studies. OBJECTIVE: To study if addition of electroanatomical mapping to Achieve catheter-guided CBA is superior for PVI. METHODS: One hundred patients were randomized between Achieve catheter-guided CBA (control group; N = 50) and Achieve catheter-guided CBA with additional EnSite voltage maps performed pre- and post-CBA (Achieve Plus group; N = 50). Confirmation of PVI was done by circular mapping catheter (CMC) and EnSite mapping by a second blinded operator. RESULTS: Despite apparent PVI in all PVs after CBA, incomplete PVI was present in 0 out of 50 patients (0%) and 0 out of 204 PVs in the Achieve Plus group versus 6 patients out of 50 (12%; P = 0.012) and 6 out of 203 PVs (3%; P = 0.013) in the control group. All 6 non-isolated PVs could be successfully isolated by additional cryoapplications. Procedure time was longer in the Achieve Plus group (75.76 ± 21.65 vs 66.06 ± 16.83 min; P = 0.014) with equal fluoroscopy times (14.85 ± 6.41 vs 14.33 ± 8.55; P = 0.732). CONCLUSION: The addition of electroanatomical EnSite mapping to the Achieve catheter improves the PVI rate of CBA and could be considered for future use. Design and Results of the Achieve Plus study. The Achieve Plus study shows that the addition of electro-anatomical EnSite mapping to the Achieve catheter improves PVI rate of CBA and could be considered for future use. See text for further explanation
    corecore